Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy

IntroductionPlasmacytoid dendritic cells (pDCs) are capable of triggering broad immune responses, yet, their scarcity in blood coupled to their reduced functionality in cancer, makes their therapeutic use for in situ activation or vaccination challenging. MethodsWe designed an in vitro differentiati...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Giovanna Fiore, Wolfgang Weckwarth, Kerstin Paetzold, Llucia Albertí Servera, Manuela Gies, Jakob Rosenhauer, Martina Antoniolli, Sina Nassiri, Stephan Schmeing, Steffen Dettling, Bhavesh Soni, Meher Majety, Anne B. Krug, Sabine Hoves, Monika Julia Wolf
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-11-01
Colecção:	Frontiers in Immunology
Assuntos:	dendritic cell differentiation hematopoietic stem cells (HSCs) human DC vaccination cancer immunotherapy plasmacytoid dendritic cells (pDCs)
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1433119/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!